Patents Expiring in December 2044
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deciphera Pharms | ROMVIMZA | vimseltinib | CAPSULE;ORAL | 219304-001 | Feb 14, 2025 | RX | Yes | No | 12,447,149 | ⤷ Get Started Free | Y | ||||
| Deciphera Pharms | ROMVIMZA | vimseltinib | CAPSULE;ORAL | 219304-002 | Feb 14, 2025 | RX | Yes | No | 12,447,149 | ⤷ Get Started Free | Y | ||||
| Deciphera Pharms | ROMVIMZA | vimseltinib | CAPSULE;ORAL | 219304-003 | Feb 14, 2025 | RX | Yes | Yes | 12,447,149 | ⤷ Get Started Free | Y | ||||
| Springworks | GOMEKLI | mirdametinib | CAPSULE;ORAL | 219389-001 | Feb 11, 2025 | RX | Yes | No | 12,390,430 | ⤷ Get Started Free | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION | ||||
| Springworks | GOMEKLI | mirdametinib | CAPSULE;ORAL | 219389-002 | Feb 11, 2025 | RX | Yes | Yes | 12,390,430 | ⤷ Get Started Free | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION | ||||
| Springworks | GOMEKLI | mirdametinib | TABLET, FOR SUSPENSION;ORAL | 219379-001 | Feb 11, 2025 | RX | Yes | Yes | 12,390,430 | ⤷ Get Started Free | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
